Antimicrobial agent use in small animals what are the prescribing practices, use of PK-PD principles, and extralabel use in the United States? - PubMed (original) (raw)

Review

. 2021 Mar;44(2):238-249.

doi: 10.1111/jvp.12921. Epub 2020 Oct 23.

Affiliations

Review

Antimicrobial agent use in small animals what are the prescribing practices, use of PK-PD principles, and extralabel use in the United States?

Mark G Papich. J Vet Pharmacol Ther. 2021 Mar.

Abstract

In this review, the availability and deficiencies of current antimicrobial agents for companion animals in the United States are described. Although several active agents are FDA-approved for small animals, there are many unmet needs. These needs are greatest for cats, for the treatment of antibiotic drug-resistant infections, and to treat new or emerging pathogens that were not considered on older labels. The older agents approved before 1997 are often outdated, unavailable, or have inaccurate labeling. Subsequently, veterinarians treat dogs and cats with many unapproved antimicrobial agents that are licensed for human use. Although these drugs may be effective, there are also concerns that this use can produce drug-resistant bacteria that may be a public health risk. Although this concern is real, there is also evidence that any antimicrobial use in small animals can produce resistant fecal bacteria and stewardship principles should aim at reducing any unnecessary antibiotic use. This could be accomplished by avoiding some of the older, ineffective, or outdated agents described in this paper. There is a need for incentives to approve new agents that will be more appropriate for treating infections in companion animals without increasing the risk of drug-resistant bacteria that could potentially be transferred to humans and the environment and create a public health risk.

Keywords: antibacterial; antibiotics; antiinfective; companion animal; pharmacokinetics.

© 2020 John Wiley & Sons Ltd.

PubMed Disclaimer

Similar articles

Cited by

References

REFERENCES

    1. Ambrose, P. G. (2006). Monte Carlo simulation in the evaluation of susceptibility breakpoints: Predicting the future: Insights from the society of infectious diseases pharmacists. Pharmacotherapy, 26(1), 129-134. https://doi.org/10.1592/phco.2006.26.1.129
    1. Ambrose, P. G., Bhavnani, S. M., & Owens, R. C. (2003). Clinical pharmacodynamics of quinolones. Infectious Disease Clinics, 17(3), 529-543. https://doi.org/10.1016/S0891-5520(03)00061-8
    1. Ambrose, P. G., Bhavnani, S. M., Rubino, C. M., Louie, A., Gumbo, T., Forrest, A., & Drusano, G. L. (2007). Pharmacokinetics-pharmacodynamics of antimicrobial therapy: It's not just for mice anymore. Clinical Infectious Diseases, 44(1), 79-86.
    1. AMDUCA (1994). Retrieved from https://www.fda.gov/animal-veterinary/acts-rules-regulations/animal-medi...
    1. Beck, K. M., Waisglass, S. E., Dick, H. L., & Weese, J. S. (2012). Prevalence of meticillin-resistant Staphylococcus pseudintermedius (MRSP) from skin and carriage sites of dogs after treatment of their meticillin-resistant or meticillin-sensitive staphylococcal pyoderma. Veterinary Dermatology, 23(4), 369. https://doi.org/10.1111/j.1365-3164.2012.01035.x

Publication types

MeSH terms

Substances

LinkOut - more resources